Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: May 17, 2011

Premium

Cristopher McReynolds has been named vice president of business development at Alverix.

He previously was CEO of Satoris. Before that, McReynolds was VP of business development for Affymetrix's molecular diagnostics business unit. Prior to working at Affy, McReynolds held the same role at Cepheid.


Illumina's stockholders have re-elected Daniel Bradbury and Roy Whitfield to serve on the firm's board of directors for three years and Gerald Möller to serve on the board for two years.

Bradbury has been a director of Illumina since 2004, while Whitfield has been a member of the board since 2007. Möller was named a director last year.


Rosetta Genomics said last week that Moshe Many has resigned from the company's board of directors. Moshe is leaving the board "due to time constraints from other professional commitments," the company said.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.